Evidence map›Paper›PMID 37627176›Full record

ArticleCancers2023

Unraveling the Role of EV-Derived miR-150-5p in Prostate Cancer Metastasis and Its Association with High-Grade Gleason Scores: Implications for Diagnosis.

Marian Cruz-Burgos, Sergio A Cortés-Ramírez, Alberto Losada-García, Miguel Morales-Pacheco, Eduardo Martínez-Martínez, Jorge Gustavo Morales-Montor, Alejandro Servín-Haddad, J Samuel Izquierdo-Luna, Griselda Rodríguez-Martínez, María Del Pilar Ramos-Godínez and 6 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marian Cruz-BurgosLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0003-3015-3836
Sergio A Cortés-RamírezLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0002-5967-0768
Alberto Losada-GarcíaLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.
Miguel Morales-PachecoLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0002-0701-980X
Eduardo Martínez-MartínezLaboratory of Cell Communication and Extracellular Vesicles, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0002-9020-559X
Jorge Gustavo Morales-MontorUrology Department, Hospital General Dr. Manuel Gea Gonzalez, Mexico City 14080, Mexico.
Alejandro Servín-HaddadUrology Department, Hospital General Dr. Manuel Gea Gonzalez, Mexico City 14080, Mexico.
J Samuel Izquierdo-LunaHospital Central Militar, Servicio de Urología, Mexico City 11600, Mexico.
Griselda Rodríguez-MartínezLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0002-3727-6743
María Del Pilar Ramos-GodínezLaboratorio de Microscopía Electrónica, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
Vanessa González-CovarrubiasLaboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0003-2072-2847
Abraham Cañavera-ConstantinoDepartamento de Anatomía Patológica, Centro Estatal de Oncología, Campeche 24090, Mexico.
Imelda González-RamírezDepartamento de Atención a la Salud, Universidad Autónoma Metropolitana, Mexico City 14387, Mexico.
Boyang SuDepartment of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada.
Hon S LeongDepartment of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada.
Mauricio Rodríguez-DorantesLaboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, Mexico.ORCID 0000-0003-4249-7222

Funding

Consejo Nacional de Ciencia y Tecnología A1-S-26446
6 · The paper itself

Abstract

Metastasis remains the leading cause of mortality in prostate cancer patients. The presence of tumor cells in lymph nodes is an established prognostic indicator for several cancer types, such as melanoma, breast, oral, pancreatic, and cervical cancers. Emerging evidence highlights the role of microRNAs enclosed within extracellular vesicles as facilitators of molecular communication between tumors and metastatic sites in the lymph nodes. This study aims to investigate the potential diagnostic utility of EV-derived microRNAs in liquid biopsies for prostate cancer. By employing microarrays on paraffin-embedded samples, we characterized the microRNA expression profiles in metastatic lymph nodes, non-metastatic lymph nodes, and primary tumor tissues of prostate cancer. Differential expression of microRNAs was observed in metastatic lymph nodes compared to prostate tumors and non-metastatic lymph node tissues. Three microRNAs (miR-140-3p, miR-150-5p, and miR-23b-3p) were identified as differentially expressed between tissue and plasma samples. Furthermore, we evaluated the expression of these microRNAs in exosomes derived from prostate cancer cells and plasma samples. Intriguingly, high Gleason score samples exhibited the lowest expression of miR-150-5p compared to control samples. Pathway analysis suggested a potential regulatory role for miR-150-5p in the Wnt pathway and bone metastasis. Our findings suggest EV-derived miR-150-5p as a promising diagnostic marker for identifying patients with high-grade Gleason scores and detecting metastasis at an early stage.

Indexed as

biomarkersexosomeextracellular vesicleslymph nodemetastasismiRNAprostate cancer

Identifiers

PMID37627176
PMCPMC10453180

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.